A PSEN2 genetic test checks your DNA for harmful changes in the PSEN2 gene, a rare cause of early-onset Alzheimer disease. The process starts with neurology referral and genetic counseling, then a blood or saliva sample and laboratory sequencing. Testing is usually offered when dementia begins before age 65 or runs across generations. The result clarifies diagnosis and helps relatives understand their own risk.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who Is Offered This Test?
- What Happens Before and During Sampling?
- How Does the Laboratory Analyze PSEN2?
- What Do Results Mean for You and Your Family?
Who Is Offered This Test?
Testing is offered when dementia begins before age 65 or with a multigenerational family history. Care starts with neurology referral, review of the family tree, and pre-test counseling about risks and family effects, as described by Mayo Clinic Press in its guide to determining when memory problems signal Alzheimer disease.
Guidelines recommend testing an affected family member first to confirm the family variant. Adult relatives at risk are then offered predictive testing only with counseling before and after.
What Happens Before and During Sampling?
The counselor reviews your personal and family history and draws a pedigree, meaning a detailed family tree. You discuss possible results, insurance effects, family stress, and how results could guide care decisions. Sample collection is brief: You can ask how long results take, who will explain them, and which relatives should attend follow-up.
- you provide a blood sample, or saliva for some panels
- the clinic labels the sample for DNA extraction and PSEN2 analysis
- the sample goes to a qualified genetics laboratory for testing
How Does the Laboratory Analyze PSEN2?
The laboratory extracts DNA from blood or saliva, then reads the PSEN2 gene code. It uses next-generation sequencing of coding exons and nearby flanking regions, plus checks for deletions and duplications.
Testing often occurs within a larger dementia panel of about 51 genes. Mayo Clinic Laboratories describes this approach in its test catalog entry for familial Alzheimer disease.
What Do Results Mean for You and Your Family?
A harmful, or pathogenic, PSEN2 variant establishes autosomal-dominant early-onset Alzheimer disease, meaning one copy can pass disease risk down. Each first-degree relative has a 50% chance of inheriting it, with onset typically from age 40 to 75, according to guidance summarized in the medical genetics counseling review.
Limits matter for decisions. PSEN2 variants explain under 1% of early-onset cases, show about 95% penetrance, meaning most but not all carriers develop disease, and cannot predict exact onset age, symptom type, severity, or speed of decline. Results raise certainty for probable Alzheimer dementia, inform family planning and screening for at-risk relatives, and can qualify carriers for studies such as the Dominantly Inherited Alzheimer Network.





